Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

Date Posted: 
2017-01-30

NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
Dr. Zoubeidi’s discovery of the protein driving the emergence of NEPC is a timely and important one. It allowed her and her team to use the new genome editing CRISPR technology to turn off the gene producing that protein. They discovered that when it was turned off, the emergence of NEPC was prevented. Her work was published Cancer Discovery.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember 2017

Movember 2017

Movember Canada's annual fundraiser for men's health issues, such as prostate cancer, testicular cancer, fitness and mental health, starts November 1st. Visit the  Vancouver Prostate Centre's fundraising page to donate to or join our team.

Employment

Work at the Vancouver Prostate Centre

Monday, January 30, 2017

Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.